Aldosterone antagonists decrease the mortality of patients with heart failure, but an observational study by Albert and colleagues has found that a surprisingly low number of patients receive aldosterone antagonists before discharge from hospital. This article highlights potential reasons for why there is such an underuse of efficient drugs in heart failure.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Approaches for monitoring and treating cardiomyopathy among cancer survivors following anthracycline or thoracic radiation treatment
Cardio-Oncology Open Access 12 May 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pitt, B. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341, 709–717 (1999).
Pitt, B. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348, 1309–1321 (2003).
Albert, N. M. et al. Use of aldosterone antagonists in heart failure. JAMA 302, 1658–1665 (2009).
Tait, S. A., Tait, J. F. & Coghlan, J. P. The discovery, isolation and identification of aldosterone: reflections on emerging regulation and function. Mol. Cell. Endocrinol. 217, 1–21 (2004).
Menard, J. The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol. Cell. Endocrinol. 217, 45–52 (2004).
Brilla, C. G., Matsubara, L. S. & Weber, K. T. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J. Mol. Cell. Cardiol. 25, 563–575 (1993).
Benard, L. et al. Effects of aldosterone on coronary function. Pharmacol. Reports 61, 58–66 (2009).
Milliez, P. et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J. Am. Coll. Cardiol. 45, 1243–1248 (2005).
Ambroisine, M. L. et al. Aldosterone-induced coronary dysfunction in transgenic mice involves the calcium-activated potassium (BKCa) channels of vascular smooth muscle cells. Circulation 116, 2435–2443 (2007).
Di Zhang, A. et al. Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling. Hypertension 52, 1060–1067 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Samuel, JL., Delcayre, C. Aldosterone antagonists are underused by clinicians. Nat Rev Cardiol 7, 125–127 (2010). https://doi.org/10.1038/nrcardio.2009.244
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2009.244
This article is cited by
-
Approaches for monitoring and treating cardiomyopathy among cancer survivors following anthracycline or thoracic radiation treatment
Cardio-Oncology (2022)
-
Effects of mineralocorticoid receptor antagonists on sex hormones and body composition in patients with primary aldosteronism
Hypertension Research (2022)
-
Newer Drugs to Reduce High Blood Pressure and Mitigate Hypertensive Target Organ Damage
Current Hypertension Reports (2022)
-
Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease
Journal of Human Hypertension (2021)
